Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously disclosed non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, securing a notional subscription amount of approximately CAD$5 million. The financing involved the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit comprising one common share and one warrant exercisable at CAD$0.77 for a three-year period. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance.
Onco-Innovations intends to allocate the net proceeds received under the sharing arrangement to advance development of its ONC010 program, which includes manufacturing and preclinical activities. Additionally, the funds will support continued development of its SynoGraph(TM) platform and provide working capital for general corporate purposes. This capital injection is crucial for the company as it progresses its oncology pipeline, particularly the ONC010 program, which targets solid tumors using patented technology licensed exclusively worldwide.
The importance of this announcement lies in its potential to accelerate Onco-Innovations' research and development efforts in oncology. With the additional funding, the company can move forward with manufacturing and preclinical studies for ONC010, a key program that could lead to novel treatments for solid tumors. The SynoGraph platform also stands to benefit, potentially enhancing the company's capabilities in developing innovative cancer therapies. For investors, this private placement signals confidence from institutional partners and provides the necessary capital to achieve near-term milestones.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more details, the full press release is available at https://ibn.fm/1Hrlg.
